Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) announced today that Taipei-based genomic services provider Gene Biodesign Enterprises Co. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. Gene Biodesign has been certified to process customer samples in their laboratory in northern Taipei county for NimbleGen array applications including Comparative Genomic Hybridization (CGH), Chromatin Immunoprecipitation-on-chip (ChIP-chip), DNA Methylation and Gene Expression. Gene Biodesign passed rigorous certification standards using the Roche NimbleGen workflow, which includes the 2 micron NimbleGen MS 200 Microarray Scanner. Gene Biodesign will provide NimbleGen array services at their location in the Mackay Memorial Hospital, a teaching hospital responsible for the clinical training of interns in modern medical studies and clinical care. The collaborative atmosphere between clinicians and genomics researchers will provide a broad perspective on their studies.

“As the latest Roche NimbleGen CSP, Gene Biodesign has made a significant investment in cutting-edge genetic analysis technologies and will provide support for these technologies in Asia”

"As the latest Roche NimbleGen CSP, Gene Biodesign has made a significant investment in cutting-edge genetic analysis technologies and will provide support for these technologies in Asia," said Jessica Chen, CEO of Gene Biodesign. "We feel we offer a superb value proposition in that we can provide certified services to academic and clinical research segments alike. We hope this collaborative effort will result in a new era of genomic studies for the life sciences and human public health."

Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc., added, "Roche NimbleGen is extremely excited to welcome Gene Biodesign to our family of certified service providers in Asia, where they will support the entire portfolio of NimbleGen array applications. We are confident that adding Gene Biodesign to the program will be a major factor in achieving high growth for Roche NimbleGen in Taiwan, as well as throughout Asia."